ACAD
31.77
-0.8
-2.46%
AEMD
0.26
+0.01
+2.00%
APRI
1.22
-0.02
-1.61%
ARNA
4.52
-0.14
-3.00%
ATEC
1.36
+0.01
+0.74%
CFN
59.75
-0.23
-0.38%
CNAT
5.34
+0.02
+0.38%
CRXM
0.2
+0.02
+11.11%
CYTX
0.47
-0.01
-1.19%
DXCM
57.92
-0.19
-0.33%
GNMK
13.18
+0.09
+0.69%
HALO
13.89
-0.12
-0.86%
ILMN
196.69
+2.8
+1.44%
INNV
0.25
+0.01
+4.17%
INO
8.62
+0.12
+1.41%
ISCO
0.06
0.00
0.00%
ISIS
71.25
+0.27
+0.37%
LGND
54.86
-0.97
-1.74%
LPTN
2.97
0.00
0.00%
MBVX
1.1
-0.15
-12.00%
MEIP
3.69
-0.1
-2.64%
MNOV
3.52
-0.12
-3.17%
MRTX
19.27
-0.15
-0.77%
MSTX
0.48
+0.00
+0.04%
NBIX
31.71
+0.13
+0.41%
NUVA
46.93
-0.26
-0.55%
ONCS
0.4
+0.00
+0.25%
ONVO
6.32
-0.05
-0.78%
OREX
5.4
+0.12
+2.27%
OTIC
32.83
+3.49
+11.90%
QDEL
24.26
-0.04
-0.16%
RCPT
110.23
+3.01
+2.80%
RGLS
18.53
+0.27
+1.48%
RMD
65.44
+3.58
+5.79%
SCIE
0.01
0.00
-7.75%
SPHS
0.45
+0.00
+1.02%
SRNE
9.96
-0.03
-0.30%
TROV
5.82
0.00
-0.06%
VICL
1.04
+0.01
+0.96%
VOLC
17.96
+0.01
+0.06%
ZGNX
1.34
+0.05
+3.88%
Home » Archive by Category

Xconomy

Device-Maker BeneChill Seeks to Raise $14.6M Through IPO

December 24, 2014 – 10:12 am | Edit Post

BeneChill, a startup established in San Diego eight years ago to develop a rapid-chilling technology to treat patients suffering from heart attacks and brain injury, intends to raise more than $14.6…

[[Click headline to continue reading.]]

What’s the Most Important Issue That Didn’t Get Addressed in 2014?

December 24, 2014 – 6:59 am | Edit Post

Immigration. Very sad and shows how deeply dysfunctional our system is. This is really hurting innovation—and other countries, like Canada, U.K., Chile and Spain, have moved way ahead of us….
[[Click headline to continue reading.]]

What’s the Most Important Issue That Didn’t Get Addressed in 2014?

December 24, 2014 – 6:59 am | Edit Post

Immigration. Very sad and shows how deeply dysfunctional our system is. This is really hurting innovation—and other countries, like Canada, U.K., Chile and Spain, have moved way ahead of us….
[[Click headline to continue reading.]]

West Coast Biotech Roundup: Gilead/AbbVie, Juno, Auspex, Bina & More

December 23, 2014 – 4:34 am | Edit Post

It was a very good year for the Bay Area’s Gilead Sciences (NASDAQ: GILD), which saw its new hepatitis C treatments— sofosbuvir (Sovaldi) and Harvoni (a combination of sofosbuvir and…
[[Click headline to continue reading.]]

Rethinking Venture Philanthropy After the Kalydeco Windfall

December 22, 2014 – 5:00 am | Edit Post

The Cystic Fibrosis (CF) Foundation’s big win in venture philanthropy can fuel constructive competition among companies developing innovative CF drugs, benefiting both patients and the healthcare…
[[Click headline to continue reading.]]

Rethinking Venture Philanthropy After the Kalydeco Windfall

December 22, 2014 – 5:00 am | Edit Post

The Cystic Fibrosis (CF) Foundation’s big win in venture philanthropy can fuel constructive competition among companies developing innovative CF drugs, benefiting both patients and the healthcare…
[[Click headline to continue reading.]]

Intrigue and Outdated Rules Complicate Big Biotech Patent Fight

December 16, 2014 – 4:30 am | Edit Post

How’s this for strange? What’s likely the most important biotech patent battle of the decade is now being fought under outmoded rules that the U.S. Congress, in a rare spasm of common…
[[Click headline to continue reading.]]

Intrigue and Outdated Rules Complicate Big Biotech Patent Fight

December 16, 2014 – 4:30 am | Edit Post

How’s this for strange? What’s likely the most important biotech patent battle of the decade is now being fought under outmoded rules that the U.S. Congress, in a rare spasm of common…
[[Click headline to continue reading.]]

West Coast Biotech Roundup: Versant, BayBio/CHI Merger, von Emster

December 11, 2014 – 11:48 am | Edit Post

A programming note: The American Society of Hematology’s annual meeting, which took place Friday through Tuesday in San Francisco, took up much of the week’s biopharma news. We’ve decided…
[[Click headline to continue reading.]]

West Coast Biotech Roundup: Versant, BayBio/CHI Merger, von Emster

December 11, 2014 – 11:48 am | Edit Post

A programming note: The American Society of Hematology’s annual meeting, which took place Friday through Tuesday in San Francisco, took up much of the week’s biopharma news. We’ve decided…
[[Click headline to continue reading.]]